ZJYL stock forecast, quote, news & analysis
Jin Medical International Ltd, along with its subsidiaries, mainly offers rehabilitation equipment... Show more
Why Jin Medical International (ZJYL) Stock Is Up +28.9% in the Last 30 Days
Key Takeaways
- ZJYL shares gained roughly 28.9% over the trailing 30 days, climbing from about $1.94 to a recent price near $2.50.
- The advance was concentrated in a sharp late-October surge, including a single-session gain of more than 26% on unusually heavy volume of roughly 3.6 million shares.
- Progress on a $159.4 million acquisition and the finalization of a related equity transfer helped remove a near-term dilution overhang and lifted sentiment.
- The rebound followed a prolonged slide that had pushed shares toward the lower end of their 52-week range of $1.53 to $8.48.
- Fundamentals remain challenged, with fiscal 2025 revenue down about 12% and net income sharply lower year over year.
- Nasdaq listing compliance and delayed regulatory filings remain key risks that could weigh on the stock.
- For additional detail, explore the company's Price Targets, Earnings, and Forecast on Tickeron's dedicated pages.
- Explore Trending AI Robots to see curated AI trading strategies across thousands of tickers.
Jin Medical International (ZJYL) Company Overview and Market Position
Jin Medical International Ltd. is a Cayman Islands holding company headquartered in Changzhou, Jiangsu Province, China, that designs, develops, manufactures, and markets wheelchairs and living-aid products for people with disabilities, the elderly, and those recovering from injury. The company operates through a variable interest entity (VIE) structure anchored by Changzhou Zhongjin Medical Co., Ltd., founded in 2006. Its product line spans wheelchairs and wheelchair components, oxygen concentrators, bath aids, rehabilitative devices, and related health products, with wheelchairs representing its primary revenue source.
The company sells primarily to distributors in Japan and China, with a customer base that remains highly concentrated—its largest Japanese distributor accounted for roughly 71% of revenue in fiscal 2025. Jin Medical operates manufacturing facilities in Changzhou and Taizhou and has been building a larger facility in Chuzhou, Anhui Province. Investors follow the stock for its exposure to China's aging-population and rehabilitation-market themes, as well as for its recent move to broaden beyond mobility devices into senior-health and biotechnology assets.
Jin Medical International (ZJYL) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, ZJYL advanced approximately 28.9%, moving from a closing price near $1.94 to a recent level around $2.50. The move was not gradual: most of the gain occurred in the final days of October, when the stock jumped more than 26% in a single session on volume many times its typical daily average, before consolidating near the $2.20 to $2.50 range.
The three-month picture is considerably more volatile. After trading near $2.00 in early August, the stock spiked to an intraday peak above $3.49 in mid-August, then gave back most of those gains through September and October, sliding to roughly $1.86 in late October before the recent rebound. As a result, the stock is up roughly 25% over the trailing three months, yet it remains well below its mid-August high and near the lower portion of its 52-week range.
What Drove ZJYL Stock Price in the Last 30 Days
The primary catalyst was progress on the company's $159.4 million acquisition of Huaxia Qiying (Beijing) Technology, a VIE-control transaction focused on ginseng-related biological resources and fermentation technology for rare ginsenosides. The agreement was signed on September 8, 2026, and closed on September 24, 2026, positioning Jin Medical to expand beyond wheelchairs into senior-health and biotechnology assets.
The late-October surge coincided with the resolution of a component of that deal. The transaction included a Kangma equity transfer that, if left incomplete by October 31, 2026, would have triggered the issuance of 622,123 additional Class A ordinary shares. The finalization of that transfer removed a near-term dilution concern, a development that helped drive the stock's sharp single-day rally alongside heavy trading volume. In a thinly traded, low-float security, such news can be amplified by speculative positioning and sentiment shifts.
What Drove ZJYL Stock Performance Over the Last Quarter
The broader multi-month trend has been shaped by conflicting forces. On one hand, the company's strategic diversification—culminating in the September closing of the Huaxia Qiying acquisition—has given investors a new growth narrative tied to China's senior-health and biotech sectors. On the other hand, the transaction was paid substantially in newly issued shares, materially increasing the share count and raising dilution and integration concerns.
Those concerns compounded existing headwinds. Fiscal 2025 results showed a 12% decline in revenue to about $20.7 million and a sharp drop in net income, while the six months ended March 31, 2026 reflected a further revenue decline and a modest net loss. At the same time, the company disclosed that it had received Nasdaq non-compliance notices for delayed periodic filings, adding delisting risk to the outlook. These factors contributed to the stock's mid-August peak and subsequent retreat, with the recent acquisition-related news providing only a partial recovery.
Trending AI Robots
Tickeron's Trending AI Robots page offers a curated view of the platform's algorithmic trading strategies. Tickeron hosts hundreds of AI-powered trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are featured in this section. The robots differ in their strategies, timeframes, and performance metrics, giving traders a way to compare approaches across markets and holding periods. Whether you are tracking momentum, swing, or longer-horizon setups, the page provides a neutral, data-driven starting point for evaluating automated strategies. Visit the Trending AI Robots section to explore the strategies currently drawing the most attention.
ZJYL Stock Forecast Drivers: What Investors Should Watch Next
Several factors are likely to shape ZJYL's direction in the months ahead. First is regulatory and listing risk: the company must resolve its Nasdaq non-compliance status and complete outstanding periodic filings, and the outcome of any appeal will be closely watched. Second is the integration and economics of the Huaxia Qiying acquisition, including whether the ginseng-related assets can be commercialized and whether further share issuance or dilution occurs.
Investors should also monitor revenue trends in the core wheelchair business and the company's heavy customer concentration, as well as the ramp-up of the new Chuzhou manufacturing facility. Broader macro considerations—including China's healthcare spending environment and currency movements—may also influence results. As always, these factors present both opportunities and risks, and they should be evaluated alongside each investor's own research and objectives.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ZJYL's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ZJYL turned positive on October 30, 2026. Looking at past instances where ZJYL's MACD turned positive, the stock continued to rise in 27 of 29 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on ZJYL as a result. In 66 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
ZJYL moved above its 50-day moving average on October 30, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ZJYL crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 9 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 78%.
Following a +25.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZJYL advanced for three days, in 162 of 188 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZJYL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ZJYL broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ZJYL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 84 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.351) is normal, around the industry mean (4.964). ZJYL's P/E Ratio (336.000) is considerably higher than the industry average of (40.591). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.750) is also within normal values, averaging (56.876).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZJYL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsOther